CAR-T靶点蛋白新品上市—荧光标记蛋白,免费提供配套CAR阳性率检测Protocol

来源: 北京百普赛斯生物科技有限公司   2018-10-10   访问量:921评论(0)

嵌合抗原受体T(CAR-T)细胞疗法是一种基于体外改造T细胞,使其表面表达特异性识别肿瘤表面抗原的受体片段的癌症免疫疗法,改造后的T细胞输入患者体内,不需要抗原递呈细胞(APC)的帮助,直接靶向体内癌细胞并发挥免疫杀伤作用。

 

对于CAR-T细胞来说,发挥肿瘤杀伤作用的有效成分是CAR阳性的T细胞,CAR-T细胞产品的包装规格及临床使用剂量是以CAR-T阳性细胞数表示的,因此,CAR转染阳性率是CAR-T质量控制的必检项,监管部门建议应采用流式细胞法检测CAR转染阳性率。目前有针对CAR不同结构区域的检测方法,包括针对CAR抗原结合位点的,比如CD19抗原,或针对轻链或铰链区的抗Fab抗体或Protein L蛋白,其中,针对抗原结合部位的CAR阳性率检测方法因其具有更好专属性而被广泛使用。

 

ACROBiosystems作为专注于医药研发领域的蛋白供应商,利用专业的蛋白研发平台、蛋白标记平台、稳定株开发平台和流式细胞分析平台,开发了一系列包括非标记、生物素标记、荧光标记等多种形式的CAR-T靶点蛋白以及配套的流式细胞法检测CAR阳性率的protocol,以助力CAR-T的研发,加速CAR-T研发的进程。目前产品已覆盖BCMA,CD19,ROR1,EGFRVIII等20余个CAR-T热门靶点.

CAR-T阳性率检测策略及蛋白产品设计

直接检测法 —— 荧光标记蛋白


产品特点

  • 靶抗原预先标记了荧光素基团
  • 可简化检测流程,节省检测时间
  • 可避免因二抗交叉反应而引起的非特异性背景


> FITC-labeled (点击分子即可查看产品详情)-> 独有产品

BCMA CD19 CD22 GPC3 MSLN Protein L


> PE-labeled (点击分子即可查看产品详情)-> 独有产品

MSLN


> 应用案例

使用FITC标记CD19蛋白检测Anti-CD19-CAR表达阳性率

293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2, 10 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled Human CD19 (20-291) (Cat. No. CD9-HF2H2).

> 如需了解更多此产品信息,可点击:ACROBiosystems官网,输入货号,即可查看产品详情,也可直接拨打:400-682-2521进行咨询

基于生物素-亲和素的检测法 —— 生物素标记蛋白


产品特点

  • 靶抗原预先标记了生物素,随后可使用荧光标记的链霉亲和素检测
  • 链霉亲和素对生物素具有极高的亲和力,两者的结合具有高度特异性
  • 可高灵敏度和高特异性地检测CAR阳性表达率

> AvitagTM biotinylated proteins -> Specially designed

BCMA CD22 CD30 CD33 CD38 CD70
EGF R EGFRVIII EpCAM FOLR1 GPC3 HER2
HGFR MSLN ROR1
 


> Chemically biotinylated proteins -> Specially designed

CD19 EpCAM HER2 MSLN Protein L


> 应用案例

使用生物素标记BCMA蛋白检测Anti-BCMA-CAR表达阳性率


Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50 µl biotinylated human BCMA protein (Cat. No. BC7-H82F0, 8 µg/ml), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma)

> 如需了解更多此产品信息,可点击:ACROBiosystems官网,输入货号,即可查看产品详情,也可直接拨打:400-682-2521进行咨询

间接检测法 —— 非标记蛋白



产品特点

  • 靶抗原带有融合表位标签,随后可使用荧光标记的表位标签抗体作为二抗进行检测
  • 可高灵敏度地检测CAR阳性表达率
  • 有可能产生因二抗交叉反应引起的非特异性背景

> Fc-tag fusion proteins -> Specially designed

BCMA CD19 CD30 CD33
CD38 CD70 EGFR FOLR1
GPC3 HER2 HGFR IL13R
MSLN MUC1 ROR1 EpCAM
 

> His-tag fusion proteins -> Specially designed

BCMA CD19 CD123 CD138 CD22 CD30
CD33 CD38 CD70 CAIX EGFR EGFRVIII
EpCAM FOLR1 GPC3 HER2 HGFR MSLN
 
ROR1

> All fusion proteins -> Specially designed

BCMA CD19 CD123 CD138 CD22 CD30
CD33 CD38 CD70 CAIX EGFR EGFRVIII
EpCAM FOLR1 GPC3 HER2 HGFR IL13RA2
 
MSLN MUCI ROR1


> 应用案例

使用Human CD19, Fc Tag蛋白检测Anti-CD19-CAR表达阳性率

293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251, 3 µg/ml) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity) (Cat. No. CD9-H5251).

> 如需了解更多此产品信息,可点击:ACROBiosystems官网,输入货号,即可查看产品详情,也可直接拨打:400-682-2521进行咨询

更多CAR-T相关内容

> 点击查看更多CD19详细信息——高亲和力CD19蛋白,专为检测CD19-CAR-T而设计

 



北京百普赛斯生物科技有限公司   商家主页

地址:北京经济技术开发区宏达北路8号5号楼4层
联系人:占女士
电话:400-682-2521
传真:
Email:order.cn@acrobiosystems.com